Billionaire Profile
Wilhelm Beier & family
Global Rank
#1270

Image: Unknown authorUnknown author | Public domain | via Wikimedia Commons

Wilhelm Beier & family

CEO, Pharmaceuticals
GERMANY
Real-Time Net Worth
$3.383B
Estimated based on Pharmaceuticals stock value as of April 20, 2026
-0.35% (24h)
Age
69
Source
Pharmaceuticals
Industry
Healthcare
Citizenship
GERMANY

Biography

Wilhelm Beier, a self-made billionaire, is the chairman of the supervisory board of Dermapharm, a German pharmaceutical company he founded in 1991. His primary source of wealth comes from his stake in Dermapharm, which manufactures generic drugs and is involved in parallel trade. With a net worth of $3.1 billion as of 2024, Beier's career has been marked by strategic business decisions and family involvement in key operational roles, contributing to his considerable wealth. His entrepreneurial spirit has led Dermapharm to expand into new areas, including medical marijuana and home shopping, showcasing his adaptability in the healthcare industry.

Fact Checked
Verified by Editorial Team
Live Data
Updated 4/20/2026

Wealth Over Time

In-Depth Profile

Early Life

Wilhelm Beier was born on April 21, 1956, in Eicherscheid, Germany. Little is known about his early life and education prior to his career in the pharmaceutical industry.

Rise to Success

Beier founded Dermapharm Holding SE in 1991, after gaining experience in the pharmaceutical sector since 1981. Dermapharm has grown into a leading German pharmaceutical manufacturer specializing in the manufacture and marketing of patent-free pharmaceuticals. A significant milestone in Dermapharm's journey came in October 2020, when the company commenced production of the COVID-19 vaccine, Comirnaty, on behalf of BioNTech. Dermapharm went public in 2018. In addition to its pharmaceutical business, Dermapharm holds a significant stake in a home shopping television channel, demonstrating diversification into consumer media.

Key Business Strategies

Beier's business strategy is based on an integrated business model, from product development and manufacturing to quality control and distribution. Dermapharm focuses on selected therapeutic areas and has a significant presence in Germany. A substantial portion of Dermapharm's revenue comes from parallel trade, leveraging price differences across European markets.

Philanthropy

Specific details about Beier's philanthropy initiatives are not readily available in public sources. However, as a high-profile individual, it is likely he is involved in various charitable activities. The precise amounts and beneficiaries are not publicly disclosed.

Career Milestones

1981

Pharmaceuticals Career

Began career in the pharmaceuticals industry, holding various positions.

1991

Founded Dermapharm

Founded Dermapharm Holding SE, a German pharmaceutical company.

2017

Chairman of the Supervisory Board

Appointed chairman of the supervisory board of Dermapharm.

2018

Dermapharm IPO

Dermapharm Holding SE went public, increasing market visibility.

2020

COVID-19 Vaccine Production

Dermapharm began producing the COVID-19 vaccine Comirnaty for BioNTech.

Philanthropy & Social Impact

Unknown

Not Available

Undisclosed

Details of philanthropic activities are not publicly available.

Business Philosophy & Leadership

Leadership Principles

Familial Control

Maintains strategic oversight with operational delegation to family members (wife, son).

Operational Pragmatism

Focuses on practical business strategies, including parallel trade and generics.